NeoGenomics Inc. priced an offering of 7 million common stock at $21.25 each.
The Fort Myers, Fla.-based company also granted underwriters a 30-day option to buy up to an additional 1,050,000 common shares at the same price.
The company, which focuses on cancer genetics testing, expects gross proceeds of $148.8 million from the offering. Net proceeds will be used for general corporate purposes.
NeoGenomics may also use the proceeds from the offer to acquire or invest in complementary business and technologies.
Morgan Stanley, SVB Leerink and William Blair acted as representatives of the underwriters and book-running managers for the offering, while Cantor, Craig-Hallum Capital Group, Needham & Co., Raymond James and Stephens Inc. acted as co-managers.